444 related articles for article (PubMed ID: 19118061)
1. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
4. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
5. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
6. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
7. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
12. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
13. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
14. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
15. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
16. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
Lefevre G; Glotin AL; Calipel A; Mouriaux F; Tran T; Kherrouche Z; Maurage CA; Auclair C; Mascarelli F
J Biol Chem; 2004 Jul; 279(30):31769-79. PubMed ID: 15145934
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
18. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate.
Wang CH; Anderson N; Li SH; Szmitko PE; Cherng WJ; Fedak PW; Fazel S; Li RK; Yau TM; Weisel RD; Stanford WL; Verma S
Circ Res; 2006 Sep; 99(6):617-25. PubMed ID: 16931795
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
20. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
